Axis Securities Initiates Buy on Biocon with Target Price of Rs 424
Axis Securities has issued a Buy rating for Biocon, setting a target price of Rs 424. The brokerage highlights Biocon's recent EMA approval for its Malaysian insulin facility, which doubles manufacturing capacity. With a shift toward deb...